1. 1. Selvetella G, and Lembo G. Mechanisms of cardiac hypertrophy. J Card Fail. 2005; 1: 263-273. https://doi.org/10.1016/j.hfc.2005.03.006.
2. Molkentin, JD. Calcineurin–NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc Res. 2004; 63: 467-475. https://doi.org/10.1016/j.cardiores.2004.01.021.
3. Frey N, and Olson, E. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Plant Biol. 2003; 65: 45-79. https://doi.org/10.1146/annurev.physiol.65.092101.142243.
4. Watkins SJ, Borthwick GM, and Arthur HM. The H9C2 cell line and primary neonatal cardiomyocyte cells show similar hypertrophic responses in vitro. In Vitro Cell. Dev Biol Anim. 2011; 47: 125-131. https://doi.org/10.1007/s11626-010-9368-1.
5. Hogan PG, Chen L, Nardone J, and Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes dev. 2003; 17: 2205-2232. https://doi.org/10.1101/gad.1102703 Genes &Dev.
6. Wilkins BJ, and Molkentin JD. Calcineurin and cardiac hypertrophy: where have we been? Where are we going? J Physiol. 2002; 541: 1-8. https://doi.org/10.1113/jphysiol.2002.017129.
7. Huang, B., He, Y., Li, S. The RCAN1.4-calcineurin/NFAT signaling pathway is essential for hypoxic adaption of intervertebral discs. Exp Mol Med 2020; 52: 865–875 https://doi.org/10.1038/s12276-020-0441-x.
8. Creamer, T.P. Calcineurin. Cell Commun Signal 2020; 18: 137. https://doi.org/10.1186/s12964-020-00636-4.
9. Grunwell, J.R., Stephenson, S.T., Mohammad, A.F. Differential type I interferon response and primary airway neutrophil extracellular trap release in children with acute respiratory distress syndrome. Sci Rep 2020; 10: 19049. https://doi.org/10.1038/s41598-020-76122-1
10. Nakata T, Toyoshima Y, Yagi T, Katsumata H, Tokita R, Minami S. Growth hormone increases regulator of calcineurin 1-4 (Rcan1-4) mRNA through c-JUN in rat liver. PLoS ONE 2020; 15(6): e0235270. https://doi.org/10.1371/journal.pone.0235270.
11. Wilkins BJ, and Molkentin JD. Calcium–calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun. 2004; 322: 1178-1191. https://doi.org/10.1016/j.bbrc.2004.07.121.
12. Rangrez, A.Y., Borlepawar, A., Schmiedel, N. The E3 ubiquitin ligase HectD3 attenuates cardiac hypertrophy and inflammation in mice. Commun Biol 2020; 3: 562 https://doi.org/10.1038/s42003-020-01289-2
13. Taigen T, De Windt LJ, Lim HW, and Molkentin J.D. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc. Natl Acad Sci U.S.A. 2000; 97(3): 1196-1201. https://doi.org/10.1073/pnas.97.3.1196.
14. Landete J U pdated knowledge about polyphenols: functions, bioavailability, metabolism, and health. Crit Rev Food Sci Nutr. 2012; 52: 936-948. https://doi.org/10.1080/10408398.2010.513779.
15. Asgary S, Sahebkar A, Afshani MR, Keshvari M, Haghjooyjavanmard S, and Rafieian‐Kopaei M, Clinical evaluation of blood pressure lowering, endothelial function improving, hypolipidemic and anti‐inflammatory effects of pomegranate juice in hypertensive subjects. Phytother Res. 2014; .28:193-199. https://doi.org/10.1002/ptr.4977
16. Shayganni E, Bahmani M, Asgary S, and Rafieian-Kopaei, M. Inflammaging and cardiovascular disease: Management by medicinal plants. Phytomedicine. 2016; 23: 1119-1126. https://doi.org/10.1016/j.phymed.2015.11.004
17. Rouhi-Boroujeni H, Heidarian E, Rouhi-Boroujeni H, Deris F and Rafieian-Kopaei, M. Medicinal plants with multiple effects on cardiovascular diseases: A systematic review. Curr Pharm Des. 2017; 23: 999-1015. https://doi.org/10.2174/1381612822666161021160524
18. Shaygannia E, Bahmani M, Zamanzad B, and Rafieian-Kopaei M. A review study on Punica granatum L. Evid Based Complement Alternat Med. 2016; 21: 221-227. https://doi.org/10.1177/2156587215598039
19. Seeram NP, Adams LS, Henning SM, Niu Y, Zhang Y, Nair MG, and Heber, D. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem. 2005; 16: 360-367. https://doi.org/10.1016/j.jnutbio.2005.01.006
20. Kannan MM, and Quine SD, Ellagic acid inhibits cardiac arrhythmias, hypertrophy and hyperlipidaemia during myocardial infarction in rats. Metabolism. 2013; 62: 52-61. https://doi.org/10.1016/j.metabol.2012.06.003.
21. Rojanathammanee L, Puig KL, and Combs CK. Pomegranate polyphenols and extract inhibit nuclear factor of activated T-cell activity and microglial activation in vitro and in a transgenic mouse model of Alzheimer disease. J Nutr. 2013; 143: 597-605. https://doi.org/10.3945/jn.112.169516.
22. Asadi F, Razmi A, Dehpour AR and Shafiei M. Tropisetron inhibits high glucose‐induced calcineurin/NFAT hypertrophic pathway in H9c2 myocardial cells. J Physiol Pharmacol. 2016; 68: 485-493. https://doi.org/10.1111/jphp.12522.
23. Kjær A, and Hesse B. Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives. Clin Physiol. 2001; 21: 661-672. https://doi.org/10.1046/j.1365-2281.2001.00371.x
24. Lim HW, De Windt LJ, Mante J, Kimball TR, Witt SA, Sussman MA and Molkentin, JD. Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition. J Mol Cell Cardiol. 2000a; 32: 697-709. https://doi.org/10.1006/jmcc.2000.1113
25. Lim HW, De Windt, LJ, Steinberg L, Taigen T, Witt SA, Kimball TR and Molkentin, JD. Calcineurin expression, activation, and function in cardiac pressure-overload hypertrophy. Circulation. 2000b; 101: 2431-2437. https://doi.org/10.1161/01.CIR.101.20.2431
26. Sieber M, and Baumgrass R. Novel inhibitors of the calcineurin/NFATc hub-alternatives to CsA and FK506? J Cell Commun Signal. 2009; 7: 25. https://doi.org/10.1186/1478-811x-7-25.
27. Lee SI, Kim BS, Kim KS, Lee S, Shin KS and Lim JS. Immune-suppressive activity of punicalagin via inhibition of NFAT activation. Biochem Biophys Res Commun. 2008; 371:799-803. https://doi.org/10.1016/j.bbrc.2008.04.150.
28. Larrosa M, Tomás-Barberán FA and Espín J C. The dietary hydrolysable tannin punicalagin releases ellagic acid that induces apoptosis in human colon adenocarcinoma Caco-2 cells by using the mitochondrial pathway. J Nutr Biochem. 2006; 17: 611-625. https://doi.org/10.1016/j.jnutbio.2005.09.004.
29. Seeram NP, Lee R, and Heber D. Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (Punica granatum L.) juice. Clin Chim Acta. 2004; 348: 63-68. https://doi.org/10.1016/j.cccn.2004.04.029.
30. Kehat I, and Molkentin JD. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation. 2010; 122: 2727-2735. https://doi.org/10.1161/CIRCULATIONAHA.110.942268.
31. Naesens M, Kuypers, DR and Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009; 4: 481-508. https://doi.org/10.2215/CJN.04800908.
32. Losso JN, Bansode RR, Trappey II, Bawadi HA and Truax R. In vitro anti-proliferative activities of ellagic acid. J Nutr Biochem. 2004; 15: 672-678. https://doi.org/10.1016/j.jnutbio.2004.06.004.
33. Tasaki M, Umemura T, Maeda M, Ishii Y, Okamura T, Inoue T, Kuroiwa Y, Hirose M and Nishikawa A. Safety assessment of ellagic acid, a food additive, in a subchronic toxicity study using F344 rats. Food Chem Toxicol. 2008; 46: 1119-1124. https://doi.org/10.1016/j.fct.2007.10.043.
2. Mechanisms of Cardiac Hypertrophy
3. Calcineurin?NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs
4. Cardiac Hypertrophy: The Good, the Bad, and the Ugly
5. The H9C2 cell line and primary neonatal cardiomyocyte cells show similar hypertrophic responses in vitro